Cel-Sci Corporation (CVM): Price and Financial Metrics
CVM Price/Volume Stats
| Current price | $1.45 | 52-week high | $3.23 |
| Prev. close | $1.46 | 52-week low | $1.04 |
| Day low | $1.41 | Volume | 82,000 |
| Day high | $1.47 | Avg. volume | 291,300 |
| 50-day MA | $1.93 | Dividend yield | N/A |
| 200-day MA | $1.96 | Market Cap | 78.27M |
CVM Stock Price Chart Interactive Chart >
Cel-Sci Corporation (CVM) Company Bio
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Latest CVM News From Around the Web
Below are the latest news stories about CEL SCI CORP that investors may wish to consider to help them evaluate CVM as an investment opportunity.
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023CEL-SCI just reported results for the fourth quarter of 2023. |
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsVIENNA, Va., December 22, 2023--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments. |
CVM: NICE To Have Your SupportBy John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Selected as Potential New Standard of Care CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this week highlighting an announcement by the British National Institute for Health and Care Excellence (NICE). The Institute has selected Multikineto to be evaluated as the potential new standard of care for |
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck CancerVIENNA, Va., December 04, 2023--UK’S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer. |
CEL-SCI Announces Closing of $5 Million Public Offering of Common StockVIENNA, Va., November 20, 2023--CEL-SCI announces closing of $5 million public offering of common stock. |
CVM Price Returns
| 1-mo | -23.28% |
| 3-mo | -49.65% |
| 6-mo | 19.83% |
| 1-year | -31.92% |
| 3-year | -94.73% |
| 5-year | -78.29% |
| YTD | -46.69% |
| 2023 | 15.74% |
| 2022 | -66.90% |
| 2021 | -39.11% |
| 2020 | 27.43% |
| 2019 | 218.82% |
Continue Researching CVM
Want to do more research on Cel Sci Corp's stock and its price? Try the links below:Cel Sci Corp (CVM) Stock Price | Nasdaq
Cel Sci Corp (CVM) Stock Quote, History and News - Yahoo Finance
Cel Sci Corp (CVM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...